Abstract 144P
Background
Patients with squamous NSCLC have a poorer prognosis than those with non-squamous histology and fewer treatment options. The phase 3 EMPOWER-Lung 1 study (NCT03088540) has demonstrated significant survival benefits of first-line (1L) cemiplimab monotherapy vs chemotherapy and an acceptable safety profile in patients with treatment-naïve squamous or non-squamous NSCLC with PD-L1 expression ≥50% and no EGFR, ALK or ROS1 aberrations. Here, we report 5-year results of patients with squamous NSCLC from this study.
Methods
In EMPOWER-Lung 1, patients were randomized to cemiplimab 350 mg IV every 3 weeks for 2 years or to investigator’s choice of chemotherapy. Primary endpoints were overall survival (OS) and progression-free survival (PFS) per Blinded Independent Review Committee. In this exploratory subgroup analysis, efficacy and safety were assessed for the subgroup of patients with squamous NSCLC. The data cutoff date was 16 January 2024 (median follow-up of 59.6 months for the overall study population).
Results
Of 565 patients with verified PD-L1 ≥50%, 245 (43%) had squamous NSCLC (cemiplimab: n = 123; chemotherapy: n = 122). Baseline characteristics were similar between treatment groups. At 5-year follow-up, cemiplimab resulted in longer OS (median 22.7 mo vs 13.5 mo; HR=0.51) and PFS (median 8.3 mo vs 5.9 mo; HR=0.44) vs chemotherapy (Table). Estimated 5-year survival probability was 25.5% for cemiplimab vs 6.9% for chemotherapy. Objective response rate (ORR) was significantly improved with cemiplimab (43.9% vs 22.1%). Approximately 42% of patients in both treatment groups had treatment-emergent adverse events (TEAEs) ≥ grade 3 (Table). Table: 144P
Cemiplimab (n=123)† | Chemotherapy (n=122)† | |
Clinical outcomes | ||
OS median (95% CI), mo | 22.7 (17.3–31.5) | 13.5 (10.0–16.2) |
HR (95% CI) | 0.51 (0.38–0.69)* | |
5-year probability OS, % (95% CI) | 25.5 (17.3–34.5) | 6.9 (2.8–13.6) |
PFS median (95% CI), mo | 8.3 (5.6–9.4) | 5.9 (4.5–6.2) |
HR (95% CI) | 0.44 (0.32–0.60)* | |
ORR, % (95% CI) | 43.9 (35.0–53.1) | 22.1 (15.1–30.5) |
Safety outcomes‡ | ||
TEAEs of any grade, n (%) | 110 (90.2) | 111 (94.1) |
Grade ≥3 TEAEs, n (%) | 51 (41.8) | 50 (42.4) |
†Subgroup from the PD-L1 ≥50% population. ‡Safety analysis set for the subgroup: cemiplimab (n=122), chemotherapy (n=118). ∗P<0.0001
Conclusions
At 5-year follow-up, 1L cemiplimab monotherapy continued to show durable clinical benefits vs chemotherapy in patients with squamous NSCLC.
Clinical trial identification
NCT03088540.
Editorial acknowledgement
Editorial support was provided by Fiona Woodward, of Alpha (a division of Prime, Knutsford, UK) funded by Regeneron Pharmaceuticals, Inc., and Sanofi. Responsibility for all opinions, conclusions, and data interpretation lies with the authors.
Legal entity responsible for the study
Regeneron Pharmaceuticals, Inc.
Funding
Regeneron Pharmaceuticals, Inc.
Disclosure
A. Baramidze: Financial Interests, Personal, Other, Travel support: Regeneron Pharmaceuticals, Inc. A. Sezer: Financial Interests, Institutional, Research Funding: Roche, Merck Sharp & Dohme, Merck Serono, AstraZeneca, Lilly, Novartis, Johnson & Johnson, Regeneron Pharmaceuticals, Inc., Sanofi. M. Gumus: Financial Interests, Personal, Other, Honoraria: Roche, Merck Sharp & Dohme, Gen İlaç, Novartis. K.D. Penkov: Financial Interests, Personal, Other, Honoraria: AstraZeneca, BeiGene, GSK, H3 Biomedicine, Janssen, Nektar, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sanofi. M. Ozguroglu: Financial Interests, Personal, Other, Honoraria: Novartis, Roche, Janssen, Sanofi, Astellas; Financial Interests, Personal, Advisory Board: Janssen, Sanofi, Astellas; Financial Interests, Personal, Other, Travel support: Bristol Myers Squibb, Janssen, AstraZeneca; Financial Interests, Personal, Speaker, Consultant, Advisor: AstraZeneca. E. Kalinka: Financial Interests, Personal, Other, Travel and accommodation support: Regeneron Pharmaceuticals, Inc. C. Zhu, F. Seebach, E. Kim, H. Magnan, J. Pouliot: Financial Interests, Personal, Full or part-time Employment: Regeneron Pharmaceuticals, Inc.; Financial Interests, Personal, Stocks/Shares: Regeneron Pharmaceuticals, Inc. All other authors have declared no conflicts of interest.
Resources from the same session
53P - Novel ex-vivo manufacturing of transiently expressed armoured CAR T cells for glioblastoma
Presenter: Saket Srivastava
Session: Poster Display session
Resources:
Abstract
54P - Superior antitumor activities of fourth-generation CAR-T cells containing three costimulatory domains targeting GD2-positive tumors
Presenter: Jatuporn Sujjitjoon
Session: Poster Display session
Resources:
Abstract
55P - Engineering of chimeric cytokine receptors (CCR) to induce IL-7 signaling to CAR-T cells for solid tumor treatment
Presenter: Marta Soria Castellano
Session: Poster Display session
Resources:
Abstract
56P - Potent antitumor efficiency of CD19-CAR T cells self-secreting PD-L1 x CD3 BiTE against aggressive B-cell lymphoma
Presenter: Jatuporn Sujjitjoon
Session: Poster Display session
Resources:
Abstract
57P - SENDER™ Directed LNP Delivery of mRNA for In Situ generation of highly potent CAR T Cells
Presenter: Biao Ma
Session: Poster Display session
Resources:
Abstract
58P - Cardiovascular outcomes of novel CAR-T cell therapies: A meta-analysis of incidence, risk factors, and management of cardiotoxicity
Presenter: Hashim Talib Hashim
Session: Poster Display session
Resources:
Abstract
59P - Long term survival data from all recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients treated with MVX-ONCO-1 during open-labelled phase I and phase IIa clinical trials
Presenter: Nicolas Mach
Session: Poster Display session
Resources:
Abstract
60P - Innovative applications of neoantigens in dendritic cell-derived exosome (DEX) therapy and their impact on personalized cancer treatment
Presenter: Ramon Gutierrez
Session: Poster Display session
Resources:
Abstract
61P - Optimized protocol for the accelerated production of dendritic cell-derived exosomes (DEXs): Achieving speed without compromising efficacy
Presenter: Ramon Gutierrez
Session: Poster Display session
Resources:
Abstract
62P - Ecto-CRT induction of NKp46 surface expression increases osimertinib-resistant lung cancer’s sensitivity to NK cells
Presenter: Sumei Chen
Session: Poster Display session
Resources:
Abstract